Cited by 493Metabolism and Genetic DisordersFolate and B Vitamins ResearchBiochemical and Molecular Research

Tetrahydrobiopterin: biochemistry and pathophysiology

Open access
Werner, Ernst R., Blau, Nenad, Thöny, Beat·2011·Biochemical Journal

Abstract

BH4 (6R-L-erythro-5,6,7,8-tetrahydrobiopterin) is an essential cofactor of a set of enzymes that are of central metabolic importance, including four aromatic amino acid hydroxylases, alkylglycerol mono-oxygenase and three NOS (NO synthase) isoenzymes. Consequently, BH4 is present in probably every cell or tissue of higher organisms and plays a key role in a number of biological processes and pathological states associated with monoamine neurotransmitter formation, cardiovascular and endothelial dysfunction, the immune response and pain sensitivity. BH4 is formed de novo from GTP via a sequence of three enzymatic steps carried out by GTP cyclohydrolase I, 6-pyruvoyltetrahydropterin synthase and sepiapterin reductase. An alternative or salvage pathway involves dihydrofolate reductase and may play an essential role in peripheral tissues. Cofactor regeneration requires pterin-4a-carbinolamine dehydratase and dihydropteridine reductase, except for NOSs, in which the BH4 cofactor undergoes a one-electron redox cycle without the need for additional regeneration enzymes. With regard to the regulation of cofactor biosynthesis, the major controlling point is GTP cyclohydrolase I. BH4 biosynthesis is controlled in mammals by hormones and cytokines. BH4 deficiency due to autosomal recessive mutations in all enzymes, except for sepiapterin reductase, has been described as a cause of hyperphenylalaninaemia. A major contributor to vascular dysfunction associated with hypertension, ischaemic reperfusion injury, diabetes and others, appears to be an effect of oxidized BH4, which leads to an increased formation of oxygen-derived radicals instead of NO by decoupled NOS. Furthermore, several neurological diseases have been suggested to be a consequence of restricted cofactor availability, and oral cofactor replacement therapy to stabilize mutant phenylalanine hydroxylase in the BH4-responsive type of hyperphenylalaninaemia has an advantageous effect on pathological phenylalanine levels in patients.

Integrity signals

Registry

Crossref · 10.1042/bj20110293

Cites

226 of 226 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In nitroglycerin tolerance, the development of tolerance was mainly due to mitochondrial ROS release and was independent of NOX, whereas activation of NOX triggered by mitochondrial ROS was the effector of endothelial dysfunction associated with nitroglycerin tolerance.

    “In this case, the development of tolerance was mainly due to mitochondrial ROS release and was independent of NOX, whereas the activation of NOX, triggered by mitochondrial ROS, was the effector of the endothelial dysfunction associated to nitroglycerin tolerance (1004).”
  • Through these enzymes, BH4 is required for nitric oxide production, metabolism of ether lipids, phenylalanine catabolism, and synthesis of amine neurotransmitters norepinephrine, epinephrine, serotonin, and dopamine.

    “Through these enzymes, BH4 is required for nitric oxide (NO) production, metabolism of ether lipids, phenylalanine catabolism, and synthesis of the amine neurotransmitters norepinephrine, epinephrine, serotonin, and dopamine.”

    From The Role of Iron Regulation in Immunometabolism and Immune-Related Disease (2019) · cites this paper as Werner et al., 2011

  • GCH1 is the rate-limiting enzyme for BH4 biosynthesis.

    “GTP cyclohydrolase I (GCH1) is the rate-limiting enzyme for BH4 biosynthesis (Werner et al., 2011; Figure 4).”

    From The Role of Iron Regulation in Immunometabolism and Immune-Related Disease (2019) · cites this paper as Werner et al., 2011

Cites

1 retracted

Flagged first, then by citations

2 of the 228 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Werner, E. R., Blau, N., & Thöny, B.
Affiliations
  • Innsbruck Medical University (AT)
  • University of Zurich (CH)
Venue
Biochemical Journal
Published
2011-08-26
Volume
438
Issue
3
Pages
397-414
ISSN
  • 0264-6021 (ISSN-L)
  • 1470-8728
OpenAlex
W2109852750
Cited by
493
References
228
Citations by year
2026: 38 · 2025: 39 · 2024: 31 · 2023: 32 · 2022: 39 · 2021: 43 · 2020: 27 · 2019: 38 · 2018: 32 · 2017: 24 · 2016: 24 · 2015: 36 · 2014: 33 · 2013: 34 · 2012: 21
FWCI
3.39
Type
journal article
Language
en
Open access
Locations
  • Biochemical Journal (publishedVersion)
  • PubMed (publishedVersion)
  • Zurich Open Repository and Archive (University of Zurich) (acceptedVersion)
  • Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
  • Zurich Open Repository and Archive (University of Zurich)
Funders
Austrian Science Fund
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
  • Health Sciences › Medicine › Rheumatology › Folate and B Vitamins Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
Keywords
tetrahydrobiopterin, BH4 biosynthesis, GTP cyclohydrolase I, sepiapterin reductase, dihydrofolate reductase, dihydropteridine reductase, aromatic amino acid hydroxylases, nitric oxide synthase, hyperphenylalaninemia, phenylalanine hydroxylase, vascular dysfunction, hypertension, ischemia-reperfusion injury, diabetes mellitus, monoamines, endothelial dysfunction, immune response, pain sensitivity
MeSH terms
Animals, Biopterins, Humans, Hypertension, Phenylalanine, Phenylalanine Hydroxylase, Phenylketonurias, Nitric Oxide Synthase

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review